This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
FTC Tetracycline Charges Denied.—
Drug companies were expected to challenge in court a Federal Trade Commission ruling that six of the nation's leading firms conspired to fix prices on tetracycline. The FTC indicated it believed the patent on tetracycline was invalid.The five-man commission claimed the right to take steps to limit or completely halt enforcement of drug patents by two of the firms, Chas. Pfizer & Co., and American Cyanamid Company. The FTC charged they had obtained the patents unfairly by withholding important information from the US Patent Office.The other three firms charged were Bristol Myers Company and Bristol Laboratories, Inc.; Olin Mathieson Chemical Corporation (Squibb), and the Upjohn Company.Pfizer and Bristol-Myers promptly denied the allegations. They and Cyanamid said they would appeal to the Federal courts.The FTC, reversing a hearing examiner's findings, ordered the five manufacturers to scrap all price lists for tetracycline and publish new
WASHINGTON NEWS. JAMA. 1963;185(8):17-18. doi:10.1001/jama.1963.03060080001001